GLUCOTRACK ANNOUNCES PRECLINICAL TESTING WITH IMPLANTABLE CONTINUOUS GLUCOSE MONITOR
2023年10月12日 - 9:30PM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical device company focused on glucose monitoring technologies
for people with diabetes and prediabetes, announced today that it
has achieved another milestone in its development of an implantable
continuous glucose monitor (CGM) by commencing preclinical animal
testing.
The Company previously announced the completion
and positive results of a laboratory-based feasibility study
demonstrating that the CGM sensor design is capable of measuring
glucose for at least two years post-implant. Further preclinical
testing, in animals, advances the development of the implantable
CGM by demonstrating that the sensor design functions as expected
after an implant procedure and 30 days thereafter.
The objectives of the preclinical animal study
were to assess the implant procedure techniques and tools as well
as to determine the acute and chronic biological effect of the
implant and the implant procedure. At this stage of development,
the study was not intended to assess sensor measurement
accuracy.
The results from the preclinical study have
established that the sensor implant procedure takes approximately
15-20 minutes to perform, does not require sophisticated implant
techniques or tools, and was able to be completed with no adverse
short-term (up to 3 days) or long-term (up to 30 days) effect on
the animals.
“This preclinical study is a key step in
furthering the development of our long-term implantable CGM
enabling us to initiate preparations for a long-term preclinical
study to assess sensor performance and accuracy,” said Paul Goode,
PhD, CEO of Glucotrack. “We are pleased to be one step closer to
bringing this technology to the millions of people living with
diabetes.”
Glucotrack is committed to commercializing an
implantable CGM with a long-term sensor life, no requirement for an
additional wearable component, and a once-only calibration.
Long-term preclinical studies on sensor performance are expected to
start in late Q4 of this year.
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK), (formerly known
as Integrity Applications, Inc.) is focused on the design,
development, and commercialization of novel technologies for people
with diabetes and prediabetes. The Company’s initial product,
Glucotrack®, is a proprietary non-invasive glucose monitoring
device designed to obtain glucose level measurements without the
pain, incremental cost, difficulty, or discomfort of conventional
invasive finger stick devices. For more information, please visit
and http://www.glucotrack.com.
Investor Contact: investors@glucotrack.com
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “expect”, “plan” and “will” are intended
to identify forward-looking statements. Readers are cautioned that
certain important factors may affect Glucotrack’s actual results
and could cause such results to differ materially from any
forward-looking statements that may be made in this news release.
Factors that may affect Glucotrack’s results include, but are not
limited to, the ability of GlucoTrack to raise additional capital
to finance its operations (whether through public or private equity
offerings, debt financings, strategic collaborations or otherwise);
risks relating to the receipt (and timing) of regulatory approvals
(including FDA approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to its
current and future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2022 as filed with the SEC on March
31, 2023.
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 4 2024 まで 5 2024
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 5 2023 まで 5 2024